VR Logo

Cytokinetics Incorporated (CYTK) download report


Healthcare | Biotechnology & Pharma Research

Cytokinetics Incorporated (CYTK) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

IPO Date: 29-Apr-2004

CEO, Pres & Director: Mr. Robert I. Blum

Sr. VP & CFO: Mr. Ching W. Jaw

Listing: NASDAQ: CYTK

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.cytokinetics.com

Key Facts

Market cap: $4,965.16 Mln

Revenue (TTM): $62.27 Mln

Earnings (TTM): $-215.92 Mln

Cash: $586.03 Mln

Total Debt: $261.71 Mln

Insider's Holding: 4.45%

Liquidity: Low

52 Week range: $29.10 - 54.74

Shares outstanding: 85,652,200

10 Years Aggregate:

  • CFO: $-471.59 Mln
  • EBITDA: $-660.93 Mln
  • Net Profit: $-808.16 Mln

Stock Performance

Time Period Cytokinetics (CYTK) S&P BSE Sensex S&P Small-Cap 600
YTD10.362.08-8.13
1 month10.949.3214.13
3 months36.319.9412.23
1 Year54.639.05-5.78
3 Years54.9916.5311.43
5 Years32.8613.769.16
10 Years28.3712.9711.05
As on 12-Aug-2022
Year Cytokinetics (CYTK) S&P Small-Cap 600 S&P BSE Sensex
2021119.3525.2721.99
202095.859.5715.75
201967.8820.8614.38
2018-22.35-9.705.87
2017-32.9211.7327.91
201616.1624.741.95
201530.59-3.36-5.03